Russell Investments Group Ltd. Has $91.14 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Russell Investments Group Ltd. raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 173,809 shares of the biopharmaceutical company’s stock after buying an additional 27,069 shares during the quarter. Russell Investments Group Ltd. owned 0.16% of Regeneron Pharmaceuticals worth $91,138,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in REGN. Activest Wealth Management lifted its position in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $27,000. Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at $27,000. Colonial Trust Advisors bought a new position in Regeneron Pharmaceuticals during the first quarter worth about $32,000. Finally, SouthState Corp boosted its stake in shares of Regeneron Pharmaceuticals by 550.0% during the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 44 shares during the period. 83.31% of the stock is owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $784.61 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $800.99. The firm has a market capitalization of $82.46 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 2.03 and a beta of 0.31. The stock’s 50 day moving average is $627.29 and its 200-day moving average is $580.60. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the previous year, the firm earned $12.46 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, November 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on REGN shares. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 14th. Scotiabank raised their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a report on Monday. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday. Sanford C. Bernstein upped their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 27th. Finally, Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $757.91.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.